Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2013, Article ID 821526, 3 pages
http://dx.doi.org/10.1155/2013/821526
Case Report

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer

1St Mary’s Hospital Imperial College Healthcare NHS Trust, London Praed Street, City of Westminster, London W2 1NY, UK
2King’s College University Hospital NHS Trust, Denmark Hill, London SE5 9RS, UK
3Brighton and Sussex University Hospitals NHS, Trust Eastern Road, Brighton BN2 5BE, UK

Received 1 April 2013; Accepted 4 June 2013

Academic Editors: N. Eke, J. P. Gearhart, and M. Sheikh

Copyright © 2013 S. Lukacs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Zhao, J. S. Schorey, M. Bong-Mastek et al., “Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity,” International Journal of Cancer, vol. 86, pp. 83–88, 2000. View at Google Scholar
  2. W. Zhao, J. S. Schorey, R. Groger, P. M. Allen, E. J. Brown, and T. L. Ratliff, “Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP,” Journal of Biological Chemistry, vol. 274, no. 8, pp. 4521–4526, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Durek, S. Brandau, A. J. Ulmer, H.-D. Flad, D. Jocham, and A. Böhle, “Bacillus-Calmette-Guerin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion,” Journal of Urology, vol. 162, no. 2, pp. 600–605, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. K. Prescott, T. B. Hargreave, G. D. Chisholm et al., “Intraveiscal Evans strain BCG therapy: quantitative immunhistochemical analysis of the immune response within the bladder wall,” Journal of Urology, vol. 161, pp. 148–152, 1992. View at Google Scholar
  5. O. T. Jansson, E. Morcos, L. Brundin et al., “The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer,” British Journal of Cancer, vol. 78, no. 5, pp. 588–592, 1998. View at Google Scholar · View at Scopus
  6. L. Bowyer, R. R. Hall, J. Reading, and M. M. Marsh, “The persistence of bacille Calmette-Guerin in the bladder after intravesical treatment for bladder cancer,” British Journal of Urology, vol. 75, no. 2, pp. 188–192, 1995. View at Google Scholar · View at Scopus
  7. C. R. W. Lockyer and D. A. Gillatt, “BCG immunotherapy for superficial bladder cancer,” Journal of the Royal Society of Medicine, vol. 94, no. 3, pp. 119–123, 2001. View at Google Scholar · View at Scopus
  8. R. Spence, R. Hay, and P. Johnston, Infection in the Cancer Patient a Practical Guide, Oxford University Press, 2006.
  9. D. L. Lamm, V. D. Stogdill, B. J. Stgdill, and R. G. Crispen, “Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer,” Journal of Urology, vol. 135, no. 2, pp. 272–274, 1986. View at Google Scholar · View at Scopus
  10. T. Hirayama, K. Matsumoto, T. Tsuboi et al., “Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer,” Acta Urologica Japonica, vol. 54, no. 2, pp. 127–129, 2008. View at Google Scholar · View at Scopus
  11. C. Beisland and D. S. Holsen, “Vitiligo—an autoimmune side-effect of intravesical bacillus Calmette-Guérin instillation?” Scandinavian Journal of Urology and Nephrology, vol. 38, no. 2, pp. 182–183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Shiba, T. Fujii, and H. Takatera, “Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report,” Acta Urologica Japonica, vol. 49, no. 10, pp. 599–601, 2003. View at Google Scholar · View at Scopus
  13. D. L. Lamm, A. Steg, L. Boccon-Gibod et al., “Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications,” Progress in Clinical and Biological Research, vol. 310, pp. 335–355, 1989. View at Google Scholar · View at Scopus
  14. G. Rival, D. Garot, E. Mercier et al., “Acute respiratory failure and septic shock induced by Mycobacterium bovis: a rare side effect of intravesical BCG therapy,” Presse Medicale, vol. 35, no. 6, part 1, pp. 980–982, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. C. Mooren, M. M. Lerch, H. Ullerich, H. Bürger, and W. Domschke, “Drug points: systemic granulomatous disease after intravesical BCG instillation,” British Medical Journal, vol. 320, no. 7229, p. 219, 2000. View at Google Scholar · View at Scopus
  16. O. Gonzalez, D. Musher, and I. Brar, “Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy,” Journal of the Royal Society of Tropical Medicine and Hygiene, vol. 36, no. 2, pp. 140–14816, 2003. View at Google Scholar